Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

By C. Hua, L. Boussemart, C. Mateus, É. Routier, C. Boutros, H. Cazenave, R. Viollet, Marina Thomas, Sévérine Roy, Naima Benannoune and 6 more. JAMA dermatology, 2016

614 citations recorded by the source corpus.

Subfields: Cell Biology, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/374b9e8a227b25398e28a6629f292312b499ac40

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. M. Lacouture

In Immunology

1. J. Wolchok
2. C. Robert
3. R. Sherry

In Oncology

1. J. Wolchok
2. C. Robert
3. K. Kerr
4. J. Haanen
5. J. Larkin
6. S. Peters
7. F. Carbonnel
8. M. Lacouture

Citations in the corpus

• Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer (2017, neutral): “Weeks to Onset, Median (range) Total (n = 134) Grade 1-2 Grade 3-4 Systemic Steroid Therapy Any 69 (51) 57 (43) 12 (9) 24 (18) 4.”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “In a small prospective study, vitiligo was found in up to 25% of patients treated with pembrolizumab [21].”
• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “which is associated with tumor response [20].”
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “002).(10) Similarly, in a phase I study of ipilimumab for patients with melanoma, rash was the most common irAE reported among responders.”
• Management of toxicities of immune checkpoint inhibitors. (2016, background): “factor for durable response.[47, 48] Pruritus is more common with ipilimumab (up to 35%)[5, 10] but still impacts 6-20% of patients treated with anti-PD-1 across several malignancies [5, 8, 10, 16, 19, 22], with rates as high as 15-19% in melanoma.”